01/10/23 2:00 PMNasdaq : EGRX low floatEagle Pharmaceuticals Provides Business Update and Guidance for 2023Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 perRHEA-AIneutral
12/21/22 4:30 PMNasdaq : EGRX conferenceslow floatEagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceEagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare ConferenceRHEA-AIneutral
12/19/22 6:50 AMNasdaq : EGRX fda approvallow floatEagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum ChemotherapyRepresents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamousRHEA-AIpositive
12/12/22 6:50 AMNasdaq : EGRX low floatEagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange Book-listed patents against AccordRHEA-AIneutral
12/01/22 6:50 AMNasdaq : EGRX low floatEagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York PalaceTopics include the clinical and scientific rationale for the Company’s hospital-based products and pipelineRHEA-AIneutral
11/16/22 6:50 AMNasdaq : EGRX low floatEagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace HotelTopics include the clinical and scientific rationale for the Company’s hospital-based products and pipelineRHEA-AIneutral
11/14/22 6:50 AMNasdaq : EGRX acquisitionlow floatEagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial PneumoniaCAL02 is being developed as an adjunct to the clinically indicatedRHEA-AIpositive
11/09/22 6:50 AMNasdaq : EGRX low floatCorrecting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 ResultsEagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain lineRHEA-AIneutral
11/07/22 6:50 AMNasdaq : EGRX low floatEagle Pharmaceuticals Reports Third Quarter 2022 ResultsQ3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted shareRHEA-AIneutral
10/31/22 6:50 AMNasdaq : EGRX conferencesearningslow floatEagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens. Scott Tarriff, President andRHEA-AIneutral